- Home
- RNA vs CELH Comparison
RNA vs CELH Comparison
Compare RNA & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNA | CELH |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 10.1B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | RNA | CELH |
|---|---|---|
| Price | $72.61 | $52.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 18 |
| Target Price | ★ $69.26 | $64.47 |
| AVG Volume (30 Days) | 1.7M | ★ 4.0M |
| Earning Date | 02-26-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | $20,868,000.00 | ★ $2,125,838,000.00 |
| Revenue This Year | $88.12 | $83.24 |
| Revenue Next Year | $18.11 | $32.45 |
| P/E Ratio | ★ N/A | $424.61 |
| Revenue Growth | ★ 106.27 | 55.07 |
| 52 Week Low | $21.51 | $21.10 |
| 52 Week High | $72.74 | $66.74 |
Technical Indicators
Market Signals| Indicator | RNA | CELH |
|---|---|---|
| Relative Strength Index (RSI) | 65.35 | 53.60 |
| Support Level | $72.40 | $54.71 |
| Resistance Level | $72.66 | $56.12 |
| Average True Range (ATR) | 0.17 | 2.02 |
| MACD | -0.10 | -0.37 |
| Stochastic Oscillator | 71.57 | 8.63 |
Price Performance
Historical ComparisonAbout RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.